Effect of sodium citrate anticoagulation in continuous renal replacement therapy on uremic patients with cerebral hemorrhage

doi:10.3969/j.issn.1004-583X.2021.05.008

Abstract

Abstract:

Objective To explore the advantages of sodium citrate anticoagulationin continuous renal replacement therapy(CRRT) on uremic patients with cerebral hemorrhage. Methods Totally 44 uremic patients with cerebral hemorrhage who were rescued from January 2012 to June 2020, were divided into sodium citrate anticoagulationin CRRT group(n=17) and heparin-free CRRT group(n=27) according to different anticoagulation methods. The survival rate and related items were compared between two groups. The patients were also divided into survival group(n=34) and death group(n=10) according to different outcome events. The value of sodium citrate anticoagulation in CRRT for uremic patients with cerebral hemorrhage was analyzed. Results The survival rate in sodium citrate anticoagulationin CRRT group was(100%) significantly higher than in heparin-free group(63.0%) (χ²=8.148,P=0.004). There were statistically significant difference in serum sodium, calcium, potassium, platelet count, white blood cell count, C-reactive protein, D-dimer, triglycerides in sodium citrate anticoagulationin CRRT group and heparin-free CRRT group. Blood B-type natriuretic peptide, calcium, CRP, D-dimer, phosphorus, white blood cell count in surival group were reduced compared with death group, but albumin, sodium, and platelet count were increased significantly in survival group. Conclusion Sodium citrate anticoagulation showed obvious advantage compared with heparin-free in CRRT on uremic patients with cerebral hemorrhage and can not only ensure adequate dialysis, but also improve the hyponatremia and hypercalcemia and reduce inflammation with the higher success rate of treatment.

Key words: uremia, cerebral hemorrhage, continuous renal replacement therapy, anticoagulant drug

CLC Number:

R692.5

Li Wenzhe, Shang Jinchun, Li Chunmei, Li Jun, Tian Fen, Cui Li, Chen Yipeng, Zhang Xiaofan, Xing Guangqun. Effect of sodium citrate anticoagulation in continuous renal replacement therapy on uremic patients with cerebral hemorrhage[J]. Clinical Focus, 2021, 36(5): 425-431.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.05.008

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I5/425

Figures/Tables 6

References 21

[1]	杜静, 王训, 高宗良. 脑出血合并维持性血液透析24例临床分析[J]. 中国实用神经疾病杂志, 2018, 21(14):1572-1576.
[2]	Rabindranath K, Adams J, Macleod AM, et al. Intermittent versus continuous renal replacement therapy for acute renal failure in adults[J]. Cochrane Database Syst Rev, 2007, (3):CD003773.
[3]	Srisawat N, Lawsin L, Uchino S, et al. Cost of acute renal replacement therapy in the intensive care unit: Results from The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) study[J]. Crit Care, 2010, 14(2):R46. doi: 10.1186/cc8933 URL
[4]	Brandenburger T, Dimski T, et al. Renal replacement therapy and anticoagulation[J]. Best Pract Res Clin Anaesthesiol, 2017, 31(3):387-401. doi: S1521-6896(17)30053-8 pmid: 29248145
[5]	张鑫, 张文博, 李莹, 等. 连续性血液净化中阿加曲班与枸橼酸钠的抗凝效果及安全性比较[J]. 武警医学, 2020, 31(2):103-106.
[6]	Liu C, Mao Z, Kang H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: A meta-analysis with trial sequential analysis of randomized controlled trials[J]. Crit Care, 2016, 20(1):144. doi: 10.1186/s13054-016-1299-0 URL
[7]	Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: Anticoagulation for continuous renal replacement therapy--heparin or citrate?[J]. Crit Care, 2011, 15(1):202. doi: 10.1186/cc9358 pmid: 21345279
[8]	Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4):c179-c184.
[9]	高晓琴, 孙小鹉, 任小军, 等. 枸橼酸钠抗凝法行血液透析治疗的临床应用价值[J]. 中国药物与临床, 2017, 17(11):1661-1663.
[10]	杨松涛, 赵娜, 胡军, 等. 应用普通含钙血液透析液局部枸橼酸抗凝血液透析的临床观察[J]. 中国血液净化, 2017, 16(7):474-476+487.
[11]	庞娟. 枸橼酸抗凝在血液透析高危出血患者中的应用[J]. 中国当代医药, 2018, 25(14):38-40.
[12]	邵汉权, 杨雪, 邓勇进, 等. 枸橼酸抗凝在肾衰竭合并脑出血患者血液滤过治疗中的应用研究[J]. 中国医学创新, 2018, 15(14):130-133.
[13]	Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: The Liver Citrate Anticoagulation Threshold (L-CAT) observational study[J]. Crit Care, 2015, 19:349. doi: 10.1186/s13054-015-1066-7 pmid: 26415638
[14]	Ricci D, Panicali L, Facchini MG, et al. Citrate anticoagulation during continuous renal replacement therapy[J]. Contrib Nephrol, 2017, 190:19-30.
[15]	Waikar SS, Curhan GC, Brunelli SM. Mortality associated with low serum sodium concent ration in maintenance hemodialysis[J]. Am J Med, 2011, 124(1):77-84. doi: 10.1016/j.amjmed.2010.07.029 URL
[16]	O’Neill WC. Targeting serum calcium in chronic kidney disease and end-stage renal disease: Is normal too high?[J]. Kidney Int, 2016, 89(1):40-45. doi: 10.1016/j.kint.2015.10.001 URL
[17]	许明杰, 洪大情, 王莉. 局部枸橼酸钠抗凝在普通血液透析中的应用进展[J]. 实用医院临床杂志, 2020, 17(3):251-255.
[18]	Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice[J]. Crit Care, 2012, 16(6):249. doi: 10.1186/cc11645 pmid: 23216871
[19]	Ding F, Song JH, Jung JY, et al. A biomimetic membrane device that modulates the excessive inflammatory response to sepsis[J]. PLoS One, 2011, 6(4):e18584. doi: 10.1371/journal.pone.0018584 URL
[20]	Strobl K, Harm S, Weber V, et al. The role of ionized calcium and magnesium in regional citrate anticoagulation and its impact on inflammatory parameters[J]. Int J Artif Organs, 2017, 40(1):15-21. doi: 10.5301/ijao.5000558 pmid: 28218351
[21]	Huguet M, Rodas L, Blasco M, et al. Clinical impact of regional citrate anticoagulation in continuous renal replacement therapy in critically ill patients[J]. Int J Artif Organs, 2017, 40(12):676-682. doi: 10.5301/ijao.5000633 pmid: 28862718

组别	例数	性别[例(%)]		年龄(岁)	既往高血压病史 [例(%)]	既往糖尿病史 [例(%)]	既往脑血管病史 [例(%)]	既往多囊肾病史 [例(%)]	脑出血前常规血液透析使用肝素/低分子肝素[例(%)]	日常使用华法林 [例(%)]	日常使用阿司匹林 [例(%)]
		男	女
		枸橼酸钠抗凝CRRT组	17									11(64.7)	6(35.2)	55.31±12.24	15(88.2)	6(35.3)	12(70.6)	2(11.8)	17(100)	7(41.2)	4(23.5)
无肝素CRRT组	27	15(55.6)	12(44.4)	55.15±13.62	26(96.3)	17(63.0)	20(74.1)	2(7.4)	27(100)	11(40.7)	8(29.6)
统计值		χ²= 0.361		t=-0.040	χ²=1.067	χ²=3.201	χ²=0.064	χ²=0.202	χ²=0.000	χ²=0.001	χ²=0.196
P值		>0.05		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

组别	例数	性别[例(%)]		年龄(岁)	既往高血压病史 [例(%)]	既往糖尿病史 [例(%)]	既往脑血管病史 [例(%)]	既往多囊肾病史 [例(%)]	脑出血前常规血液透析使用肝素/低分子肝素[例(%)]	日常使用华法林 [例(%)]	日常使用阿司匹林 [例(%)]
		男	女
		枸橼酸钠抗凝CRRT组	17									11(64.7)	6(35.2)	55.31±12.24	15(88.2)	6(35.3)	12(70.6)	2(11.8)	17(100)	7(41.2)	4(23.5)
无肝素CRRT组	27	15(55.6)	12(44.4)	55.15±13.62	26(96.3)	17(63.0)	20(74.1)	2(7.4)	27(100)	11(40.7)	8(29.6)
统计值		χ²= 0.361		t=-0.040	χ²=1.067	χ²=3.201	χ²=0.064	χ²=0.202	χ²=0.000	χ²=0.001	χ²=0.196
P值		>0.05		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

项目	枸橼酸钠抗凝CRRT组(n=17)	无肝素CRRT组(n=27)	Z值/χ²值	P值
出血量(ml)	31.690(15.549,39.061)	17.298(6.756,51.687)	-0.845	0.398
格拉斯哥评分(分)	10.000(4.000,15.000)	10.000(3.750,13.250)	-0.328	0.743
破入脑室[例(%)]	3(6.8)	2(4.6)	1.086	0.297
脑出血部位[例(%)]			4.475	0.929
基底节区	4(23.5)	8(29.6)	0.196	0.658
额顶颞枕叶	4(23.5)	7(25.9)	0.032	0.858
蛛网膜下腔	3(17.6)	3(11.1)	0.378	0.538
脑干	1(5.9)	4(14.8)	0.826	0.363
丘脑	2(11.8)	2(7.4)	0.240	0624
放射冠区	1(5.9)	1(3.7)	0.114	0.736
小脑	1(5.9)	1(3.7)	0.114	0.735
硬膜下血肿	0	1(3.7)	0.644	0.422
脑室旁	1(5.9)	0	1.625	0.202

项目	枸橼酸钠抗凝CRRT组(n=17)	无肝素CRRT组(n=27)	Z值/χ²值	P值
出血量(ml)	31.690(15.549,39.061)	17.298(6.756,51.687)	-0.845	0.398
格拉斯哥评分(分)	10.000(4.000,15.000)	10.000(3.750,13.250)	-0.328	0.743
破入脑室[例(%)]	3(6.8)	2(4.6)	1.086	0.297
脑出血部位[例(%)]			4.475	0.929
基底节区	4(23.5)	8(29.6)	0.196	0.658
额顶颞枕叶	4(23.5)	7(25.9)	0.032	0.858
蛛网膜下腔	3(17.6)	3(11.1)	0.378	0.538
脑干	1(5.9)	4(14.8)	0.826	0.363
丘脑	2(11.8)	2(7.4)	0.240	0624
放射冠区	1(5.9)	1(3.7)	0.114	0.736
小脑	1(5.9)	1(3.7)	0.114	0.735
硬膜下血肿	0	1(3.7)	0.644	0.422
脑室旁	1(5.9)	0	1.625	0.202

组别	例数	钠(mmol/L)								钙(mmol/L)											磷(mmol/L)
组别	例数	治疗前			治疗后					治疗前					治疗后						治疗前							治疗后
枸橼酸钠抗凝CRRT组	17	135.725±6.064			141.289±3.382					2.217±0.218					2.155±0.219						1.460(1.345, 2.315)							1.745(1.485, 2.103)
无肝素CRRT组	27	138.548±4.678			138.415±4.061					2.082±0.293					2.438±0.296						1.560(1.320, 2.230)							1.960(1.530, 2.420)
统计值		t=-1.712			t=2.466					t=0.163					t=-3.603						Z=-0.274							Z=-1.299
P值		0.095			0.018					0.103					0.001						0.784							0.194
组别	例数	钾(mmol/L)						血肌酐(μmol/L)												尿素氮(mmol/L)
组别	例数	治疗前	治疗后					治疗前					治疗后							治疗前							治疗后
枸橼酸钠抗凝CRRT组	17	4.908±0.987	4.327±0.507					821.050±337.104					570.378±186.234							25.205(16.800, 34.013)							21.310(14.590,28.183)
无肝素CRRT组	27	4.706±0.703	4.771±0.643					635.562±309.111					698.715±337.762							22.560(15.815, 36.775)							21.135(17.460,33.510)
统计值		t=-0.756	t=-2.445					t=1.793					t=-1.462							Z=-0.428							Z=-1.098
P值		0.454	0.019					0.081					0.151							0.669							0.272
组别	例数	ALT(U/L)							AST(U/L)																白蛋白(g/L)
组别	例数	治疗前		治疗后					治疗前								治疗后								治疗前							治疗后
枸橼酸钠抗凝CRRT组	17	16.119±2.611		20.069±2.362					13.300(9.350, 15.700)								15.750(12.275,23.923)								35.994±5.104							35.006±4.868
无肝素CRRT组	27	14.676±1.484		24.402±4.285					15.200(11.650, 21.625)								18.700(12.150,25.375)								32.610±6.642							31.339±7.922
统计值		t=0.516		t=-0.784					Z=-1.657								Z=-0.418								t=1.724							t=1.899
P值		0.609		0.437					0.098								0.676								0.093							0.065
组别	例数	总蛋白(g/L)										甘油三酯(mmol/L)										总胆固醇(mmol/L)
组别	例数	治疗前					治疗后					治疗前						治疗后				治疗前							治疗后
枸橼酸钠抗凝CRRT组	17	60.150(53.550, 67.050)					60.500(57.675,64.025)					2.270±0.439						1.391±0.604				4.080(3.533, 4.258)							4.110(3.223,5.193)
无肝素CRRT组	27	61.215(52.325, 67.775)					62.550(58.300,69.200)					2.480±0.338						2.215±1.060				4.585(3.743, 5.335)							3.990(3.775,4.380)
统计值		Z=0.041					Z=-1.386					t=-0.382						t=-3.206				Z=0.594							Z=-0.084
P值		0.967					0.166					0.704						0.003				0.553							0.993
组别	例数	LDL-C(mmol/L)						HDL-C(mmol/L)													血糖(mmol/L)
组别	例数	治疗前	治疗后					治疗前						治疗后							治疗前							治疗后
枸橼酸钠抗凝CRRT组	17	2.501±0.717	2.632±0.873					1.160(0.890, 1.283)						1.120(0.890,1.535)							5.660(4.415, 8.783)							7.755(4.790,10.190)
无肝素CRRT组	27	2.658±1.028	2.523±0.824					1.180(1.010, 1.280)						1.085(0.943,1.275)							6.010(5.183, 7.795)							6.340(5.323,8.295)
统计值		t=-0.530	t=0.415					Z=-0.360						Z=-0.842							Z=-0.152							Z=-0.776
P值		0.599	0.680					0.719						0.400							0.879							0.438
组别	例数	DD(μg/L)									CRP(mg/L)													白细胞计数(×10⁹/L)
组别	例数	治疗前				治疗后					治疗前								治疗后					治疗前							治疗后
枸橼酸钠抗凝CRRT组	17	580.000 (265.000, 1180.000)				450.000 (317.500,542.500)					6.430 (2.245, 19.760)								2.030 (0.500,7.750)					6.010 (5.285, 8.960)							5.975 (4.513,7.308)
无肝素CRRT组	27	850.000 (530.000, 1222.000)				845.000 (405.000,1360.000)					9.670 (1.770, 38.270)								14.920 (1.323,41.463)					7.895 (6.248, 10.095)							7.410 (6.633,8.623)
统计值		Z=-1.290				Z=-2.244					Z=-0.145								Z=-2.784					Z=-1.354							Z=-2.313
P值		0.197				0.025					0.885								0.005					0.176							0.021
组别	例数	血小板计数(×10⁹/L)								血红蛋白(g/L)													尿酸(μmol/L)
组别	例数	治疗前			治疗后					治疗前						治疗后							治疗前							治疗后
枸橼酸钠抗凝CRRT组	17	170.130±60.650			193.00±59.754					100.310±22.123						97.940±18.580							414.944±102.891							362.513±98.781
无肝素CRRT组	27	183.540±71.768			148.92±63.082					97.580±23.204						91.310±21.346							397.808±118.975							384.042±165.014
统计值		t=-0.615			t=2.292					t=0.371						t=1.068							t=0.470							t=-0.515
P值		0.542			0.027					0.713						0.292							0.641							0.609
组别	例数	PTH(pmol/L)														BNP(pg/ml)
组别	例数	治疗前						治疗后								治疗前										治疗后
枸橼酸钠抗凝CRRT组	17	204.350(90.005, 281.625)						210.650(148.475,519.975)								1454.850(393.600, 3978.750)										265.200(102.475, 627.600)
无肝素CRRT组	27	199.100(137.200, 334.500)						195.960(118.300,526.400)								375.050(144, 325, 804.325)										617.300(195.400, 930.900)
统计值		Z=-0.675						Z=-0.605								Z=-2.620										Z=-1.313
P值		0.511						0.545								0.009										0.189